SCHEMBL3283090

SCHEMBL3283090

O=Cc1sccc1OCCO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.39
ALDH1A1 P00352 4/20 0.36
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
RECQL P46063 1/20 0.34
KMT2A Q03164 4/20 0.33
GAA P10253 3/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 2/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
TUBB1 Q9H4B7 1/20 0.32
CYP1A2 P05177 1/20 0.31
PTGDR2 Q9Y5Y4 2/20 0.31
FDPS P14324 1/20 0.31
LOX P28300 1/20 0.31
AOC3 Q16853 1/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29018563 0.82 ALDH1A1 (0.36) ALDH1A1HTTSMN1; SMN2HPGDFDPS
SCHEMBL11713104 0.78 MEN1 (0.41) ALDH1A1HPGDKMT2AGAAMEN1
SCHEMBL1871186 0.78 MEN1 (0.41) ALDH1A1HPGDKMT2AGAAMEN1
SCHEMBL11713106 0.78 MEN1 (0.41) ALDH1A1HPGDKMT2AGAAMEN1
SCHEMBL20505646 0.78 KMT2A (0.49) ALDH1A1HTTSMN1; SMN2HPGDKMT2A
SCHEMBL28234656 0.74 KEAP1 (0.38) ALDH1A1HPGDKMT2AMEN1MAPT
SCHEMBL10305111 0.74 KMT2A (0.31) KMT2A
SCHEMBL10769655 0.73 KMT2A (0.36) ALDH1A1KMT2AKDM4EMEN1CYP1A2
SCHEMBL28272400 0.72 RIPK1 (0.36) HPGD
SCHEMBL21939309 0.71 L3MBTL1 (0.52) ALDH1A1SMN1; SMN2RECQLKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569317-B2 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives NOVARTIS AG (CH) 2013-10-29 US disclosed
US-8569317-B2 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives NOVARTIS AG (CH) 2013-10-29 US disclosed
US-8569317-B2 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives NOVARTIS AG (CH) 2013-10-29 US disclosed
US-7696216-B2 Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives NOVARTIS AG (CH) 2010-04-13 US disclosed
US-7696216-B2 Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives NOVARTIS AG (CH) 2010-04-13 US disclosed
US-7696216-B2 Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives NOVARTIS AG (CH) 2010-04-13 US disclosed
US-20100063075-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives ALTMANN EVA 2010-03-11 US disclosed
US-20100063075-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives ALTMANN EVA 2010-03-11 US disclosed
US-20100063075-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives ALTMANN EVA 2010-03-11 US disclosed
EP-1585521-B8 DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE NOVARTIS AG (CH) 2009-03-25 EP disclosed
EP-1585521-B1 DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE NOVARTIS AG (CH) 2008-06-18 EP disclosed
EP-1844780-A2 Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone Novartis Pharma AG (CH) 2007-10-17 EP disclosed
EP-1844780-A2 Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone Novartis Pharma AG (CH) 2007-10-17 EP disclosed
US-20060079685-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives NOVARTIS AG (CH) 2006-04-13 US disclosed
EP-1585521-A2 DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2005-10-19 EP disclosed
WO-2004056365-A2 DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE NOVARTIS AG (CH) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079685-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives PTH1R, PTMS, CYP24A1 IDO1 3080/4885ALDH1A1 3159/4885HTT 4570/4885
US-20100063075-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives PTH1R, PTMS, CYP24A1 IDO1 3010/4885ALDH1A1 3107/4885HTT 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.